Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PETRA study of AZD5305 alone and in combination in advanced solid tumors
CTR20220423Phase 2Active
- Sponsor
- AstraZeneca
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of saruparib in Nonhematologic neoplasms (3 arms), sponsored by AstraZeneca. Primary endpoints: Incidence of adverse events and serious adverse events, Dose-limiting toxicities and 2 more. Started Aug 2022; status: active.
02
Drugs
saruparib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20220423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220423.